Clinical Trial Update: Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR [Phase 2]

View source ↗

Summary

A Phase 2 study assessed switching from the efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen to the emtricitabine/rilpivirine/tenofov…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
• COMPLERA (Emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)

Snippet

Sponsor: Gilead Sciences | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2013-04-19